A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT ID: NCT06339008
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
450 participants
INTERVENTIONAL
2024-04-26
2028-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants can expect study participation to last up to 29.5 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Study of LY3471851 in Healthy Participants
NCT05565729
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis
NCT07291284
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
NCT00524836
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
NCT00103454
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
NCT06046391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lebrikizumab every 2 weeks (Q2W)/ every 4 weeks (Q4W)
Lebrikizumab will be given as a subcutaneous (SC) injection. Participants will receive background therapy with intranasal corticosteroids (INCS).
LY3650150
Administered SC
Standard therapy for INCS
Administered as intranasal spray
Lebrikizumab Q2W/every 8 weeks (Q8W)
Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS.
LY3650150
Administered SC
Standard therapy for INCS
Administered as intranasal spray
Placebo Q2W/Q4W
Placebo matching Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS.
Placebo
Administered SC
Standard therapy for INCS
Administered as intranasal spray
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3650150
Administered SC
Placebo
Administered SC
Standard therapy for INCS
Administered as intranasal spray
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a positive skin prick test (SPT) with indoor allergens and/or positive serum antigen-specific immunoglobulin E (IgE) for indoor allergens ≥0.70 kU/L, utilizing a validated assay (central laboratory).
* The participant must have clinical symptoms at study entry associated with positive perennial allergen as tested by the SPT or a positive serum antigen-specific IgE test.
* A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.
* Participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.
Exclusion Criteria
* Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy. However, individuals who discontinued subcutaneous or sublingual immunotherapy for ≥3 years prior to randomization are eligible.
* Have received treatment with any rescue medication during the run-in period.
* Have received treatment with any biologic or systemic immunosuppressants, including Janus Kinase inhibitors (JAK) for inflammatory disease or autoimmune disease prior to the baseline visit:
* Any current or prior use of biologics indicated for asthma or AD are prohibited.
* B cell-depleting biologics, including rituximab, within 6 months.
* Other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.
* Systemic immunosuppressants, including JAK inhibitors, within 4 weeks prior to baseline.
* Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 8 weeks of the maintenance period.
* Anticipates significant changes in their daily environmental exposure.
* Has a known history of recurrent acute or chronic sinusitis.
* Female participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allergy and Asthma Specialists Medical Group
Huntington Beach, California, United States
310 Clinical Research
Inglewood, California, United States
Allergy & Asthma Associates of Southern California dba. Southern California Research
Laguna Niguel, California, United States
Allergy and Asthma
San Diego, California, United States
Asthma and Allergy Associates, PC
Colorado Springs, Colorado, United States
Allergy and Asthma Diagnostic Center
Tallahassee, Florida, United States
University of South Florida
Tampa, Florida, United States
Northwestern University
Chicago, Illinois, United States
Asthma Allergy Center of Chicago
River Forest, Illinois, United States
Bluegrass Allergy Research
Lexington, Kentucky, United States
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan, United States
Clinical Research Institute
Minneapolis, Minnesota, United States
University of Missouri Hospital
Columbia, Missouri, United States
Allergy and Asthma Consultants
St Louis, Missouri, United States
Asthma and Allergy Center
Bellevue, Nebraska, United States
Circuit Clinical/Hudson-Essex Allergy
Belleville, New Jersey, United States
Circuit Clinical/Mercer Allergy and Pulmonary Associates
Hamilton, New Jersey, United States
Dr. Patrick Perin
Teaneck, New Jersey, United States
Smith Allergy and Asthma
Horseheads, New York, United States
Allergy Partners
Asheville, North Carolina, United States
Allergy Partners
Asheville, North Carolina, United States
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States
Northwest Research Center
Portland, Oregon, United States
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania, United States
AARA Research Center
Dallas, Texas, United States
Kerrville Allergy and Asthma Associates
Kerrville, Texas, United States
Allergy, Asthma & Sinus Center
Greenfield, Wisconsin, United States
Hôpital Erasme, Service Pharmacie
Brussels, , Belgium
Pneumocare
Erpent, , Belgium
UZ Gent
Ghent, , Belgium
UZ Leuven, Pharmacy
Leuven, , Belgium
Hôpital de la Citadelle
Liège, , Belgium
Internal Medicine Building
Beijing, , China
Department of Nasal Allergy
Beijing, , China
The Third Xiangya Hospital of Central South University
Changsha, , China
GCP Pharmacy
Guangzhou, , China
GCP Pharmacy
Guangzhou, , China
Zhejiang People's Hospital
Hangzhou, , China
Jingzhou Central Hospital
Jingzhou, , China
The First Affiliated Hospital of Nanchang University
Nanchang, , China
The Second Affiliated Hospital of Nanchang University
Nanchang, , China
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, , China
The First Affiliated Hospital of Guangxi Medical University
Nanning, , China
Tongji Hospital
Shanghai, , China
Outpatient building
Wuhan, , China
Outpatient Department, Union Hospital
Wuhan, , China
Renmin Hospital of Wuhan University
Wuhan, , China
Northern Jiangsu People's Hospital
Yangzhou, , China
Yangzhou University
Yangzhou, , China
Zhongshan City People's Hospital
Zhongshan, , China
Charité - Universitätsmedizin Berlin Klinik für Dermatologie
Berlin, , Germany
Praxis für HNO und Allergologie
Dresden, , Germany
Universitätsklinikum Carl Gustav Carus an der TU
Dresden, , Germany
IKF Pneumologie
Frankfurt am Main, , Germany
Siteworks - Zentrum für klinische Studien Heidelberg
Heidelberg, , Germany
Universitätsklinik Marburg,Hals-, Nasen- und Ohrenklinik, Sektion Rhinologie und Allergologie
Marburg, , Germany
Zentrum für Rhinologie und Allergologie
Weisbaden, , Germany
Polimedica PTG Kielce
Kielce, , Poland
Centrum Medyczne Promed ul. Olszańska 5G
Krakow, , Poland
Malopolskie Centrum Alergologii
Krakow, , Poland
gab. 114, ul. inż. pilota Wigury
Lodz, , Poland
ETG Lublin
Lublin, , Poland
Centrum Alergologii Teresa Hofman Sp z.o.o.
Piła, , Poland
EMED Centrum Usług Medycznych
Rzeszów, , Poland
ClinMedica Research
Skierniewice, , Poland
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp Z O.O.
Tarnów, , Poland
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp Z O.O.
Tarnów, , Poland
ETG Warszawa
Warsaw, , Poland
ALL-MED - Specjalistyczna Opieka Medyczna
Wroclaw, , Poland
Inje University Haeundae Paik Hospital
Busan, , South Korea
B1F, Pharmacy department, Gachon University Gil Medical Center
Incheon, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Kyunghee University Hospital at Gangdong
Seoul, , South Korea
Gangnam Severance Hospital 211
Seoul, , South Korea
SMG-SNU Boramae Medical Center
Seoul, , South Korea
Clinical trial Pharmacy
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J2T-MC-KGBT
Identifier Type: OTHER
Identifier Source: secondary_id
2023-508817-18-00
Identifier Type: OTHER
Identifier Source: secondary_id
18789
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.